PE20070828A1 - Composicion farmaceutica que contiene una sal de glicopirronio - Google Patents

Composicion farmaceutica que contiene una sal de glicopirronio

Info

Publication number
PE20070828A1
PE20070828A1 PE2006001485A PE2006001485A PE20070828A1 PE 20070828 A1 PE20070828 A1 PE 20070828A1 PE 2006001485 A PE2006001485 A PE 2006001485A PE 2006001485 A PE2006001485 A PE 2006001485A PE 20070828 A1 PE20070828 A1 PE 20070828A1
Authority
PE
Peru
Prior art keywords
glycopyronium
salt
pharmaceutical composition
composition containing
methyl
Prior art date
Application number
PE2006001485A
Other languages
English (en)
Inventor
Stephen Paul Collingwood
Barbara Haeberlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35580403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070828A1 publication Critical patent/PE20070828A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA INHALABLE QUE CONTIENE: A) SAL DE GLICOPIRRONIO TAL COMO BROMURO DE GLICOPIRRONIO; B) UN COMPUESTO DE FORMULA I, DONDE T ES 5-METIL-2-TIENILO, N-METIL-2-PIRROLILO, CICLOPROPILO, 2,5-DIMETIL-3-FURILO, ENTRE OTROS. DICHA COMPOSICION EJERCE UN EFECTO SINERGICO EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS TALES COMO ASMA O ENFERMEDAD OBSTRUCTIVA PULMONAR
PE2006001485A 2005-11-21 2006-11-21 Composicion farmaceutica que contiene una sal de glicopirronio PE20070828A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0523654.2A GB0523654D0 (en) 2005-11-21 2005-11-21 Organic compounds

Publications (1)

Publication Number Publication Date
PE20070828A1 true PE20070828A1 (es) 2007-09-05

Family

ID=35580403

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001485A PE20070828A1 (es) 2005-11-21 2006-11-21 Composicion farmaceutica que contiene una sal de glicopirronio

Country Status (14)

Country Link
US (1) US20080274189A1 (es)
EP (1) EP1954267A1 (es)
JP (1) JP2009516663A (es)
KR (1) KR20080069194A (es)
CN (1) CN101309684A (es)
AR (1) AR057904A1 (es)
AU (1) AU2006314724A1 (es)
BR (1) BRPI0618786A2 (es)
CA (1) CA2628172A1 (es)
GB (1) GB0523654D0 (es)
PE (1) PE20070828A1 (es)
RU (1) RU2008124836A (es)
TW (1) TW200803841A (es)
WO (1) WO2007057223A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN102665678B (zh) 2009-12-23 2014-07-02 奇斯药制品公司 用于copd的联合治疗
EA021917B1 (ru) 2009-12-23 2015-09-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированная терапия астмы и copd
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
HUE039513T2 (hu) 2013-12-30 2019-01-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény
RS60299B1 (sr) 2014-09-09 2020-07-31 Vectura Ltd Formulacija koja obuhvata glikopirolat, postupak i uređaj
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CA3152578A1 (en) 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0217504D0 (en) * 2002-07-29 2002-09-04 Novartis Ag Organic compounds
PT1713473E (pt) * 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease

Also Published As

Publication number Publication date
US20080274189A1 (en) 2008-11-06
CN101309684A (zh) 2008-11-19
JP2009516663A (ja) 2009-04-23
EP1954267A1 (en) 2008-08-13
AU2006314724A1 (en) 2007-05-24
TW200803841A (en) 2008-01-16
GB0523654D0 (en) 2005-12-28
BRPI0618786A2 (pt) 2011-09-13
WO2007057223A1 (en) 2007-05-24
CA2628172A1 (en) 2007-05-24
AR057904A1 (es) 2007-12-26
KR20080069194A (ko) 2008-07-25
RU2008124836A (ru) 2009-12-27

Similar Documents

Publication Publication Date Title
PE20070828A1 (es) Composicion farmaceutica que contiene una sal de glicopirronio
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
MA35285B1 (fr) Indazoles
EA201291310A1 (ru) Композиция ингибитора jak для местного применения
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
CO6382129A2 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
HN2012000031A (es) Terapia de combinacion para el tratamiento de la diabetes
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
MY151295A (en) Pyrimidyl indoline compound
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
CY1109743T1 (el) Παραγωγα των 2-βενζοϋλο-ιμιδαζοπυριδινων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales

Legal Events

Date Code Title Description
FC Refusal